Palatin Technologies (PTN) Falls 40% Following Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease

Visit StreetInsider.com at http://www.streetinsider.com/Momentum+Movers/Palatin+Technologies+%28PTN%29+Falls+40%25+Following+Results+of+PL9643+MELODY-1+Pivotal+Phase+3+Clinical+Trial+in+Patients+with+Dry+Eye+Disease/22848179.html for the full story.